NCT00257738View on ClinicalTrials.gov

0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
BIOLOGICAL

MAGE-A3

Three dose levels of MAGE-A3 vaccine will be tested : 500ug, 1000 ug and 1500 ug

BIOLOGICAL

HPV-16 vaccine

Three dose levels of HPV- 16 vaccine will be tested : 500ug, 1000 ug and 1500 ug

Trial Locations (1)

21201-1619

University of Maryland School of Medicine, Baltimore

All Listed Sponsors
collaborator

National Institute of Dental and Craniofacial Research (NIDCR)

NIH

lead

University of Maryland, Baltimore

OTHER

NCT00257738 - 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter